French pharmaceutical giant Sanofi has announced that it has begun clinical trials in Japan to confirm the efficacy and safety of the new coronavirus under development by administering it to humans.
Clinical trials are being conducted in various countries around the world, including Japan, and approval applications will be submitted based on the results.
According to Sanofi's announcement, the final stage of clinical trials is planned to be conducted in more than 35,000 people around the world, including the United States, including five medical institutions in Japan, and began in Japan on the 12th of this month. ..
The vaccine to be developed is a "genetically modified protein vaccine" that artificially creates and administers something similar to the protein on the surface of the virus to produce antibodies that attack the virus in the body.
In clinical trials, two vaccines, one for conventional viruses and one for the mutant virus "beta strain" confirmed in South Africa, are more effective and safer than ineffective fake drugs. I plan to confirm.
The company plans to apply for approval in Japan based on the results of clinical trials, and if it can be put to practical use, it will be produced at a factory in Gifu prefecture.
Sanofi says, "We will also prepare for production so that the vaccine will be delivered as soon as possible."